Joe Todisco, CorMedix CEO

CorMedix hit with sec­ond CRL for an­ti­fun­gal treat­ment, cit­ing man­u­fac­tur­ing and API is­sues

Fol­low­ing a C-suite shuf­fle, a shut­ter­ing of its Eu­ro­pean op­er­a­tions and a CRL for its treat­ment to pre­vent blood­stream in­fec­tions in pa­tients un­der­go­ing chron­ic …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.